<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39397941</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2405-8440</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>19</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>15</Day></PubDate></JournalIssue><Title>Heliyon</Title><ISOAbbreviation>Heliyon</ISOAbbreviation></Journal><ArticleTitle>Mechanism of non-competitive inhibition of the SARS-CoV-2 3CL protease dimerization: Therapeutic and clinical promise of the lichen secondary metabolite perlatolinic acid.</ArticleTitle><Pagination><StartPage>e38445</StartPage><MedlinePgn>e38445</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e38445</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.heliyon.2024.e38445</ELocationID><Abstract><AbstractText>In response to the COVID-19 pandemic, identifying effective treatments against SARS-CoV-2 has become of utmost importance. This study elucidates the mechanism by which perlatolinic acid, a lichen-derived secondary metabolite, non-competitively inhibits the dimerization of the SARS-CoV-2 3CL protease, a pivotal enzyme in the virus lifecycle. Utilising a combination of kinetic parameter determination, inhibition assays, and molecular docking studies, we demonstrate that perlatolinic acid effectively disrupts the enzymatic function by binding at the dimer interface with a measured <i>K</i> <sub><i>i</i></sub> value of 0.67 μM, thereby impeding the protease catalytic activity essential for viral replication. Molecular docking studies further corroborate the binding specificity of perlatolinic acid to the dimer interface, which is attributed to the loss of key interactions essential for dimerization, consequently impairing catalytic activity, highlighting its potential as a scaffold for developing broad-spectrum antiviral drugs. Despite a dose-dependent cytotoxicity of perlatolinic acid, its <i>TC</i> <sub><i>50</i></sub> is approximately 43 times higher than the <i>K</i> <sub><i>i</i></sub> value. Our findings suggest that perlatolinic acid holds significant promise as a lead compound for the development of new therapeutics against COVID-19, warranting further investigation and clinical evaluation. In conclusion, the study sheds light on the therapeutic potential of natural compounds in combating SARS-CoV-2, paving the way for the exploration of lichen secondary metabolites as a reservoir of potential antiviral agents.</AbstractText><CopyrightInformation>© 2024 Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fagnani</LastName><ForeName>Lorenza</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, via Vetoio 1, 67100, L'Aquila, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellio</LastName><ForeName>Pierangelo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, via Vetoio 1, 67100, L'Aquila, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Giulio</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, via Vetoio 1, 67100, L'Aquila, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nazzicone</LastName><ForeName>Lisaurora</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, via Vetoio 1, 67100, L'Aquila, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iorio</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, via Vetoio 1, 67100, L'Aquila, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petricca</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, via Vetoio 1, 67100, L'Aquila, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franceschini</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, via Vetoio 1, 67100, L'Aquila, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertarini</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Life Sciences, University of Modena and Reggio Emilia, Via Campi 103, 41125, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tondi</LastName><ForeName>Donatella</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Life Sciences, University of Modena and Reggio Emilia, Via Campi 103, 41125, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Celenza</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, via Vetoio 1, 67100, L'Aquila, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Heliyon</MedlineTA><NlmUniqueID>101672560</NlmUniqueID><ISSNLinking>2405-8440</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">3CL protease dimer interface</Keyword><Keyword MajorTopicYN="N">Broad-spectrum COVID-19 therapeutics</Keyword><Keyword MajorTopicYN="N">Lichen metabolites against COVID-19</Keyword><Keyword MajorTopicYN="N">Perlatolinic acid antiviral activity</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 3CL protease inhibition</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39397941</ArticleId><ArticleId IdType="pmc">PMC11471173</ArticleId><ArticleId IdType="doi">10.1016/j.heliyon.2024.e38445</ArticleId><ArticleId IdType="pii">S2405-8440(24)14476-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Liang, P.-H. Characterization and inhibition of SARS-coronavirus main protease. Curr. Top. Med. Chem. 6 (4), 361–376.</Citation><ArticleIdList><ArticleId IdType="pubmed">16611148</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand, K.; Ziebuhr, J.; Wadhwani, P.; Mesters, J. R.; Hilgenfeld, R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 300 (5626), 1763–1767.</Citation><ArticleIdList><ArticleId IdType="pubmed">12746549</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuiken, T.; Fouchier, R. A. M.; Schutten, M.; Rimmelzwaan, G. F.; van Amerongen, G.; van Riel, D.; Laman, J. D.; de Jong, T.; van Doornum, G.; Lim, W.; Ling, A. E.; Chan, P. K. S.; Tam, J. S.; Zambon, M. C.; Gopal, R.; Drosten, C.; van der Werf, S.; Escriou, N.; Manuguerra, J.-C.; Stöhr, K.; Peiris, J. S. M.; Osterhaus, A. D. M. E. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 362 (9380), 263–270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7112434</ArticleId><ArticleId IdType="pubmed">12892955</ArticleId></ArticleIdList></Reference><Reference><Citation>Drosten, C.; Günther, S.; Preiser, W.; van der Werf, S.; Brodt, H.-R.; Becker, S.; Rabenau, H.; Panning, M.; Kolesnikova, L.; Fouchier, R. A. M.; Berger, A.; Burguière, A.-M.; Cinatl, J.; Eickmann, M.; Escriou, N.; Grywna, K.; Kramme, S.; Manuguerra, J.-C.; Müller, S.; Rickerts, V.; Stürmer, M.; Vieth, S.; Klenk, H.-D.; Osterhaus, A. D. M. E.; Schmitz, H.; Doerr, H. W. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348 (20), 1967–1976.</Citation><ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId></ArticleIdList></Reference><Reference><Citation>Fouchier, R. A. M.; Kuiken, T.; Schutten, M.; van Amerongen, G.; van Doornum, G. J. J.; van den Hoogen, B. G.; Peiris, M.; Lim, W.; Stöhr, K.; Osterhaus, A. D. M. E. Koch's postulates fulfilled for SARS virus. Nature 423 (6937), 240–240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095368</ArticleId><ArticleId IdType="pubmed">12748632</ArticleId></ArticleIdList></Reference><Reference><Citation>Ksiazek, T. G.; Erdman, D.; Goldsmith, C. S.; Zaki, S. R.; Peret, T.; Emery, S.; Tong, S.; Urbani, C.; Comer, J. A.; Lim, W.; Rollin, P. E.; Dowell, S. F.; Ling, A.-E.; Humphrey, C. D.; Shieh, W.-J.; Guarner, J.; Paddock, C. D.; Rota, P.; Fields, B.; DeRisi, J.; Yang, J.-Y.; Cox, N.; Hughes, J. M.; LeDuc, J. W.; Bellini, W. J.; Anderson, L. J.; SARS working group. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348 (20), 1953–1966.</Citation><ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronavirus Disease (COVID-19) – World Health Organization.</Citation></Reference><Reference><Citation>Goyal, B.; Goyal, D. Targeting the dimerization of the main protease of coronaviruses: a potential broad-spectrum therapeutic strategy. ACS Comb. Sci. 22 (6), 297–305.</Citation><ArticleIdList><ArticleId IdType="pubmed">32402186</ArticleId></ArticleIdList></Reference><Reference><Citation>Majumdar, M.; Singh, V.; Misra, T. K.; Roy, D. N. In silico studies on structural inhibition of SARS-CoV-2 main protease Mpro by major secondary metabolites of andrographis paniculata and cinchona officinalis. Biologia (Bratisl) 77 (5), 1373–1389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8883239</ArticleId><ArticleId IdType="pubmed">35250036</ArticleId></ArticleIdList></Reference><Reference><Citation>Song, Z.; Xu, Y.; Bao, L.; Zhang, L.; Yu, P.; Qu, Y.; Zhu, H.; Zhao, W.; Han, Y.; Qin, C. From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses 11 (1), 59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6357155</ArticleId><ArticleId IdType="pubmed">30646565</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, L.; Lin, D.; Sun, X.; Curth, U.; Drosten, C.; Sauerhering, L.; Becker, S.; Rox, K.; Hilgenfeld, R. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science 368 (6489), 409–412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164518</ArticleId><ArticleId IdType="pubmed">32198291</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal, R.; Gautam, R. K.; Chopra, H.; Dubey, A. K.; Singla, R. K.; Rayan, R. A.; Kamal, M. A. Comparative highlights on MERS-CoV, SARS-CoV-1, SARS-CoV-2, and NEO-CoV. EXCLI J 21, 1245–1272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9727256</ArticleId><ArticleId IdType="pubmed">36483910</ArticleId></ArticleIdList></Reference><Reference><Citation>de Wit, E.; van Doremalen, N.; Falzarano, D.; Munster, V. J. SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 14 (8), 523–534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7097822</ArticleId><ArticleId IdType="pubmed">27344959</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, P.; Yang, X.-L.; Wang, X.-G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H.-R.; Zhu, Y.; Li, B.; Huang, C.-L.; Chen, H.-D.; Chen, J.; Luo, Y.; Guo, H.; Jiang, R.-D.; Liu, M.-Q.; Chen, Y.; Shen, X.-R.; Wang, X.; Zheng, X.-S.; Zhao, K.; Chen, Q.-J.; Deng, F.; Liu, L.-L.; Yan, B.; Zhan, F.-X.; Wang, Y.-Y.; Xiao, G.-F.; Shi, Z.-L. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579 (7798), 270–273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahase, E. Covid-19: pfizer's Paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ 375, n2713.</Citation><ArticleIdList><ArticleId IdType="pubmed">34750163</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal, B.; Goyal, D. Targeting the dimerization of the main protease of coronaviruses: a potential broad-spectrum therapeutic strategy. ACS Comb. Sci. 22 (6), 297–305.</Citation><ArticleIdList><ArticleId IdType="pubmed">32402186</ArticleId></ArticleIdList></Reference><Reference><Citation>Celenza, G.; Segatore, B.; Setacci, D.; Perilli, M.; Brisdelli, F.; Bellio, P.; Piovano, M.; Garbarino, J. A.; Amicosante, G.; Nicoletti, M. Antibacterial activity of selected metabolites from Chilean lichen species against methicillin-resistant staphylococci. Nat. Prod. Res. 27 (17), 1528–1531.</Citation><ArticleIdList><ArticleId IdType="pubmed">23030591</ArticleId></ArticleIdList></Reference><Reference><Citation>Astuti, I.; Ysrafil, null. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): an overview of viral structure and host response. Diabetes Metabol. Syndr. 14 (4), 407–412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7165108</ArticleId><ArticleId IdType="pubmed">32335367</ArticleId></ArticleIdList></Reference><Reference><Citation>Desmarets, L.; Millot, M.; Chollet-Krugler, M.; Boustie, J.; Camuzet, C.; François, N.; Rouillé, Y.; Belouzard, S.; Tomasi, S.; Mambu, L.; Séron, K. Lichen or associated micro-organism compounds are active against human coronaviruses. Viruses 15 (9), 1859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10536056</ArticleId><ArticleId IdType="pubmed">37766264</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagnani, L.; Nazzicone, L.; Bellio, P.; Franceschini, N.; Tondi, D.; Verri, A.; Petricca, S.; Iorio, R.; Amicosante, G.; Perilli, M.; Celenza, G. Protocetraric and salazinic acids as potential inhibitors of SARS-CoV-2 3CL protease: biochemical, cytotoxic, and computational characterization of depsidones as slow-binding inactivators. Pharmaceuticals 15 (6), 714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9227325</ArticleId><ArticleId IdType="pubmed">35745633</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison, J. F.; Walsh, C. T. The behavior and significance of slow-binding enzyme inhibitors. Adv. Enzymol. Relat. Area Mol. Biol. 61, 201–301.</Citation><ArticleIdList><ArticleId IdType="pubmed">3281418</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira, J. C.; Fadl, S.; Rabeh, W. M. Key dimer interface residues impact the catalytic activity of 3CLpro, the main protease of SARS-CoV-2. J. Biol. Chem. 298 (6), 102023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9091064</ArticleId><ArticleId IdType="pubmed">35568197</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei, P.; Fan, K.; Chen, H.; Ma, L.; Huang, C.; Tan, L.; Xi, D.; Li, C.; Liu, Y.; Cao, A.; Lai, L. The N-terminal octapeptide acts as a dimerization inhibitor of SARS coronavirus 3C-like proteinase. Biochem. Biophys. Res. Commun. 339 (3), 865–872.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092940</ArticleId><ArticleId IdType="pubmed">16329994</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou, C.-Y.; Chang, H.-C.; Hsu, W.-C.; Lin, T.-Z.; Lin, C.-H.; Chang, G.-G. Quaternary structure of the severe acute respiratory syndrome (SARS) coronavirus main protease. Biochemistry 43 (47), 14958–14970.</Citation><ArticleIdList><ArticleId IdType="pubmed">15554703</ArticleId></ArticleIdList></Reference><Reference><Citation>Gan, C.; Jia, X.; Fan, S.; Wang, S.; Jing, W.; Wei, X. Virtual screening and molecular dynamics simulation to identify potential SARS-CoV-2 3CLpro inhibitors from a natural product compounds library. Acta Virol. 67, 12464.</Citation></Reference><Reference><Citation>Tam, N. M.; Pham, D.-H.; Hiep, D. M.; Tran, P.-T.; Quang, D. T.; Ngo, S. T. Searching and designing potential inhibitors for SARS-CoV-2 Mpro from natural sources using atomistic and deep-learning calculations. RSC Adv. 11 (61), 38495–38504.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9044063</ArticleId><ArticleId IdType="pubmed">35493244</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, N.; Yang, Z.; Liu, Y.; Dang, X.; Zhang, Q.; Wang, J.; Liu, X.; Zhang, J.; Pan, X. Identification of a putative SARS-CoV-2 main protease inhibitor through in silico screening of self-designed molecular library. Int. J. Mol. Sci. 24 (14), 11390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10379331</ArticleId><ArticleId IdType="pubmed">37511149</ArticleId></ArticleIdList></Reference><Reference><Citation>Pennisi, R.; Gentile, D.; Rescifina, A.; Napoli, E.; Trischitta, P.; Piperno, A.; Sciortino, M. T. An integrated in silico and in vitro approach for the identification of natural products active against SARS-CoV-2. Biomolecules 14 (1), 43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10813393</ArticleId><ArticleId IdType="pubmed">38254643</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, G.; Venegas, F. A.; Rueda, A. M.; Weerasinghe, N. W.; Uggowitzer, K. A.; Thibodeaux, C. J.; Moitessier, N.; Mittermaier, A. K. A naturally occurring G11S mutation in the 3C-like protease from the SARS-CoV-2 virus dramatically weakens the dimer interface. Protein Sci. 33 (1), e4857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10731504</ArticleId><ArticleId IdType="pubmed">38058248</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Y.-N.; Zhu, G.-H.; Liu, W.; Xiong, Y.; Hu, Q.; Zhuang, X.-Y.; Jia, G.-H.; Zhang, W.-D.; Ge, G.-B. Discovery and characterization of the covalent SARS-CoV-2 3CLpro inhibitors from Ginkgo biloba extract via integrating chemoproteomic and biochemical approaches. Phytomedicine 114, 154796.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10052880</ArticleId><ArticleId IdType="pubmed">37037086</ArticleId></ArticleIdList></Reference><Reference><Citation>Hicks, E. G.; Kandel, S. E.; Lampe, J. N. Identification of aloe-derived natural products as prospective lead scaffolds for SARS-CoV-2 main protease (Mpro) inhibitors. Bioorg. Med. Chem. Lett. 66, 128732.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9004148</ArticleId><ArticleId IdType="pubmed">35427739</ArticleId></ArticleIdList></Reference><Reference><Citation>Panagiotopoulos, A. A.; Karakasiliotis, I.; Kotzampasi, D.-M.; Dimitriou, M.; Sourvinos, G.; Kampa, M.; Pirintsos, S.; Castanas, E.; Daskalakis, V. Natural polyphenols inhibit the dimerization of the SARS-CoV-2 main protease: the case of fortunellin and its structural analogs. Molecules 26 (19), 6068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8512273</ArticleId><ArticleId IdType="pubmed">34641612</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng, S.-C.; Chang, G.-G.; Chou, C.-Y. Mutation of glu-166 blocks the substrate-induced dimerization of SARS coronavirus main protease. Biophys. J. 98 (7), 1327–1336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2849084</ArticleId><ArticleId IdType="pubmed">20371333</ArticleId></ArticleIdList></Reference><Reference><Citation>Ureña-Vacas, I.; González-Burgos, E.; Divakar, P. K.; Gómez-Serranillos, M. P. Lichen depsidones with biological interest. Planta Med. 88 (11), 855–880.</Citation><ArticleIdList><ArticleId IdType="pubmed">34034351</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingelfinger, R.; Henke, M.; Roser, L.; Ulshöfer, T.; Calchera, A.; Singh, G.; Parnham, M. J.; Geisslinger, G.; Fürst, R.; Schmitt, I.; Schiffmann, S. Unraveling the pharmacological potential of lichen extracts in the context of cancer and inflammation with a broad screening approach. Front. Pharmacol. 11, 1322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7509413</ArticleId><ArticleId IdType="pubmed">33013369</ArticleId></ArticleIdList></Reference><Reference><Citation>Coelho, L. C. Antimicrobial Activity of Secondary Metabolites and Lectins from Plants. 396–406.</Citation></Reference><Reference><Citation>Bellio, P.; Di Pietro, L.; Mancini, A.; Piovano, M.; Nicoletti, M.; Brisdelli, F.; Tondi, D.; Cendron, L.; Franceschini, N.; Amicosante, G.; Perilli, M.; Celenza, G. SOS response in bacteria: inhibitory activity of lichen secondary metabolites against Escherichia coli RecA protein. Phytomedicine 29, 11–18.</Citation><ArticleIdList><ArticleId IdType="pubmed">28515022</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuzmič, P. DynaFit--a software package for enzymology. Methods Enzymol. 467, 247–280.</Citation><ArticleIdList><ArticleId IdType="pubmed">19897096</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh, A. K.; Raghavaiah, J.; Shahabi, D.; Yadav, M.; Anson, B. J.; Lendy, E. K.; Hattori, S.; Higashi-Kuwata, N.; Mitsuya, H.; Mesecar, A. D. Indole Chloropyridinyl ester-derived SARS-CoV-2 3CLpro inhibitors: enzyme inhibition, antiviral efficacy, structure–activity relationship, and X-ray structural studies. J. Med. Chem. 64 (19), 14702–14714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8457330</ArticleId><ArticleId IdType="pubmed">34528437</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>